Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 20, 2026

A retiree says he'd have millions if he invested his Social Security in the S&P 500 — here's what he's missing

View original at finance.yahoo.com
A retiree says he'd have millions if he invested his Social Security in the S&P 500 — here's what he's missing Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • If his Social Security contributions had instead been invested in the S&P 500, the total would be in the millions, and his monthly drawdown would be many times greater than his actual Social Security benefit.

    60% confidence
  • Without Social Security, almost four in ten older adults would be living below the poverty line.

    60% confidence
  • One-fifth of Social Security beneficiaries receive disability or young survivor benefits, not just retirement benefits.

    60% confidence
  • Mason's simple calculation comparing Social Security contributions to S&P 500 returns does not capture the full scope of a life, including disability protection, survivor benefits, and the social safety net function of Social Security.

    60% confidence
  • The risk of disability or premature death is greater than many people realize. Some 8% of recent entrants to the labor force will die before reaching the full retirement age, and many more will become disabled.

    60% confidence
  • The Social Security Act was designed to give some measure of protection to the average citizen and his family against the loss of a job and against poverty-ridden old age, even if it cannot insure 100% of the population against 100% of life's hazards.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com